- Home
- KMPR vs AKRO Comparison
KMPR vs AKRO Comparison
Compare KMPR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMPR
- AKRO
- Stock Information
- Founded
- KMPR 1990
- AKRO 2017
- Country
- KMPR United States
- AKRO United States
- Employees
- KMPR N/A
- AKRO N/A
- Industry
- KMPR Property-Casualty Insurers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- KMPR Finance
- AKRO Health Care
- Exchange
- KMPR Nasdaq
- AKRO Nasdaq
- Market Cap
- KMPR 4.0B
- AKRO 3.9B
- IPO Year
- KMPR N/A
- AKRO 2019
- Fundamental
- Price
- KMPR $63.23
- AKRO $54.20
- Analyst Decision
- KMPR Strong Buy
- AKRO Strong Buy
- Analyst Count
- KMPR 4
- AKRO 6
- Target Price
- KMPR $78.25
- AKRO $82.50
- AVG Volume (30 Days)
- KMPR 551.7K
- AKRO 1.8M
- Earning Date
- KMPR 08-04-2025
- AKRO 08-08-2025
- Dividend Yield
- KMPR 2.02%
- AKRO N/A
- EPS Growth
- KMPR N/A
- AKRO N/A
- EPS
- KMPR 5.35
- AKRO N/A
- Revenue
- KMPR $4,689,100,000.00
- AKRO N/A
- Revenue This Year
- KMPR $3.29
- AKRO N/A
- Revenue Next Year
- KMPR $12.29
- AKRO N/A
- P/E Ratio
- KMPR $11.83
- AKRO N/A
- Revenue Growth
- KMPR N/A
- AKRO N/A
- 52 Week Low
- KMPR $53.57
- AKRO $21.02
- 52 Week High
- KMPR $73.01
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- KMPR 50.91
- AKRO 62.96
- Support Level
- KMPR $62.56
- AKRO $53.61
- Resistance Level
- KMPR $64.23
- AKRO $56.49
- Average True Range (ATR)
- KMPR 1.34
- AKRO 2.40
- MACD
- KMPR -0.09
- AKRO -0.08
- Stochastic Oscillator
- KMPR 57.49
- AKRO 65.93
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.